ReviewNeuropsychopharmacology reports2026
Pharmacological Management, Safety, and Outcomes in Bipolar Disorder: An Integrated Narrative Review of Clinical and Translational Evidence.
Review in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBipolar disorder (BD) is a chronic psychiatric condition that requires careful pharmacological management. Ensuring treatment effectiveness, safety, adherence, and proper monitoring is essential, especially in pediatric, pregnant, and cognitively impaired patients.
objectiveTo review the available evidence on treatment outcomes, safety, adherence, and monitoring in bipolar disorder.
methodsA literature search was conducted using PubMed, Scopus, Web of Science, and Google Scholar. A comprehensive review of systematic reviews, meta-analyses, cohort studies, clinical trials, and case reports was performed. This review was guided by the Scale for the Assessment of Narrative Review Articles (SANRA) criteria. The findings were synthesized qualitatively.
resultsThis review highlights important challenges and therapeutic considerations in bipolar disorder management. Medication adherence and laboratory monitoring compliance were generally poor. Sleep disturbances were associated with poorer functional outcomes. Combination therapy reduced the risk of manic and depressive recurrence but may lower overall functioning in some patients. Lithium showed favorable long-term outcomes, including reduced sickness absence and lower mortality, whereas pregabalin was linked to poorer occupational outcomes. Untreated bipolar disorder during pregnancy was associated with prematurity and low birth weight. Mechanistically, lithium, valproate, and emerging agents may modulate neuroplasticity and intracellular signaling pathways; however, evidence for cognitive improvement remains limited and inconsistent.
conclusionLithium and combination therapies improve relapse prevention, cognitive outcomes, and mortality. However, adverse effects and poor adherence remain challenges. Individualized strategies, regular monitoring, and tailored interventions are essential to optimize care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.